CareDx (NASDAQ:CDNA) Stock: Insider Michael Goldberg Sells 13,800 Shares

CareDx, Inc. (NASDAQ:CDNA – Get Free Report) Director Michael Goldberg sold 13,800 shares of the company’s stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $79.15, for a total transaction of $1,092,270.00. Following the transaction, the director directly owned 48,526 shares of the company’s stock, valued at approximately $3,840,832.90. This represents a 22.14% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

CareDx Stock Down 5.3%

Shares of CDNA traded down $4.16 during mid-day trading on Monday, hitting $73.72. The company had a trading volume of 1,030,726 shares, compared to its average volume of 981,669. The business’s 50-day simple moving average is $66.34 and its 200-day simple moving average is $36.70. CareDx, Inc. has a 1-year low of $15.15 and a 1-year high of $90.87. The stock has a market cap of $3.87 billion, a PE ratio of 30.85 and a beta of 2.50.

CareDx (NASDAQ:CDNA – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.25 by $0.45. CareDx had a net margin of 25.86% and a return on equity of 9.74%. The firm had revenue of $139.36 million during the quarter, compared to analyst estimates of $121.96 million. During the same quarter in the prior year, the business posted $0.03 earnings per share. CareDx’s revenue for the quarter was up 39.3% compared to the same quarter last year. On average, sell-side analysts expect that CareDx, Inc. will post 1.00 earnings per share for the current year.

Hedge Funds Weigh In On CareDx

Hedge funds and other institutional investors have recently made changes to their positions in the business. Cetera Investment Advisers purchased a new position in CareDx in the third quarter valued at about $310,000. Entropy Technologies LP boosted its position in shares of CareDx by 9.9% in the third quarter. Entropy Technologies LP now owns 14,231 shares of the company’s stock worth $925,000 after buying an additional 1,284 shares during the period. FORA Capital LLC purchased a new stake in shares of CareDx in the third quarter worth about $1,640,000. Empowered Funds LLC acquired a new stake in shares of CareDx in the third quarter valued at about $15,356,000. Finally, Teton Advisors LLC acquired a new stake in shares of CareDx in the third quarter valued at about $403,000.

Analyst Ratings Changes

CDNA has been the subject of several research reports. BTIG Research boosted their price objective on shares of CareDx from $81.00 to $92.00 and gave the company a “buy” rating in a research note on Friday, October 30th. Craig Hallum raised CareDx from a “hold” rating to a “buy” rating and set a $64.00 target price on the stock in a research report on Monday, August 3rd. HC Wainwright reiterated a “neutral” rating and issued a $46.00 target price on shares of CareDx in a report on Friday, July 31st. Weiss Ratings raised CareDx from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Finally, Zacks Research upgraded CareDx from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 5th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $70.33.

Check Out Our Latest Stock Analysis on CDNA

About CareDx

(Get Free Report)

CareDx, Inc. is a precision medicine company focused on organ transplantation. It develops and provides diagnostic tests and related services to help clinicians assess transplant recipients and monitor their health over time. Its offerings include AlloSure, a donor-derived cell-free DNA test used to help monitor for organ rejection, and AlloMap, a gene-expression test used in heart transplant care. CareDx also provides histocompatibility testing, clinical tools, and services designed to support patients and transplant care teams.

See Also

Insider Buying and Selling by Quarter for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.